MARKET

ABBV

ABBV

Abbvie Inc
NYSE
178.81
+0.72
+0.40%
After Hours: 179.50 +0.69 +0.39% 17:02 02/26 EST
OPEN
178.84
PREV CLOSE
178.09
HIGH
179.79
LOW
178.00
VOLUME
4.31M
TURNOVER
0
52 WEEK HIGH
179.79
52 WEEK LOW
127.03
MARKET CAP
315.86B
P/E (TTM)
65.77
1D
5D
1M
3M
1Y
5Y
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
FDA approved Simlandi injection, as an interchangeable biosimilar to AbbVie Inc’s Humira. The biosimilar is indicated for adult arthritis. In 2023, Humira was one of the highest-grossing pharmaceutical products in the world.
Benzinga · 17h ago
AbbVie Inc. ($ABBV) Bullish Structure Calling for More Upside Since July 2023.
AbbVie Inc. (ABBV) forecast was posted back in July 2023. The stock is expected to remain supported in a series of 4s and 5s with a target higher towards $186 – 204. We follow up on Abbvie's forecast and take a look at the latest count.
Barchart · 17h ago
Alvotech/Teva win FDA approval for Humira biosimilar
Seeking Alpha · 20h ago
Weekly Report: what happened at ABBV last week (0219-0223)?
Weekly Report · 21h ago
A $100,000 Dividend Snowball From A 5.5%-Yielding All-Weather Portfolio
Home Dividends Analysis Dividend Strategy A $100,000 Dividending Snowball From A 5.5%-Yielding All-Weather Portfolio. Charlie Munger and Ray Dalio provide wisdom on how to invest for long-term financial freedom. We combine their wisdom with the power of dividend growth investing to build a high-yielding all-weather dividend growth snowball.
Seeking Alpha · 1d ago
3 Dividend Stocks That Are No-Brainer Buys Right Now
Three Fool.com contributors have identified dividend stocks they think are no-brainers to buy right now. AbbVie, Eli Lilly and Gilead Sciences are among three companies that pay big dividends. The drugmakers are on track to return to solid growth in 2025.
The Motley Fool · 2d ago
Super Micro Computer Can Raise Money for Free. It's Bad News for Interest Rates.
Super Micro Computer raised $1.5 billion by selling convertible notes with a 0% interest rate. Randall Forsyth: Corporations are taking advantage of low interest rates in the capital markets. He says corporate credit spreads are narrowing as expectations for the Fed to lower rates have lessened. Forsyth says corporate debt is "priced to perfection"
Barron‘s · 3d ago
Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More
NASDAQ · 3d ago
More
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, ELAHERE, IMGN-151, Pivekimab Sunirine and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities and more. The Company offers a PINK1 activator which is designed to address mitochondrial dysfunction.

Webull offers AbbVie Inc stock information, including NYSE: ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.